Observational Study of the Safety and Efficacy of Norditropin® in Adult Patients With Growth Hormone Deficiency

Novo Nordisk

Status: Completed

Conditions: Adult Growth Hormone Deficiency; Growth Hormone Disorder

Treatments: Drug: somatropin

Study type: Observational

Funder types: Industry

Identifiers

NCT01109017

GH-3811

U1111-1114-6250 (Other Identifier)

JapicCTI-101122 (Registry Identifier)

Details and patient eligibility

About

This study is conducted in Japan. The aim of this observational study is to collect information about the safety and efficacy of Norditropin® long-term treatment of growth hormone deficiency in adults.

Enrollment: 387 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Severe adult growth hormone deficiency

Exclusion criteria

• Known or suspected allergy to study product(s) or related products
• Previous participation in the study
• Diabetes Mellitus
• Presence of malignant tumor(s)
• Pregnant or likely to get pregnant

Trial design

387 participants in 1 patient group

Norditropin®

Treatment:

Drug: somatropin